Want to join the conversation?
$EQR, which competes with rivals $AIV and $UDR, said it revised its guidance range for same-store revenue to 4.5-5.0% from 4.50-5.25%. On the same-store OpEx side, the guidance range is revised to 2.5-3.0% from its 2.5-3.5% growth for the full-year 2016. $EQR expects to reduce its NOI range to 5-6% from its previous guidance range of 5.0-6.5%.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?